Our Core

We aspire to make a lasting impact for patients with cardiac diseases

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

Management Team

Claudia Ulbrich
Claudia Ulbrich
MD
CEO & Co-Founder
Thomas Thum
Prof. Thomas Thum
MD, PhD
CSO & Founder
Rahul Agrawal
Rahul Agrawal
MD
CMO

Board

Claus Andersson
Claus Andersson
PhD
Simone Botti
Simone Botti
PhD
Christoph Broja
CFA
Martin Crook
Martin Crook
PhD
Luc Debruyne
Ulrich Granzer
Ulrich Granzer
PhD
Russell Greig
Russell Greig
PhD
Chairman
Markus Hosang
Markus Hosang
PhD
Vice-chairman

Scientific Advisory Board

Prof. Johann Bauersachs
MD
Javed Butler
Prof. Javed Butler
MD
Prof. Perry Elliott
MD
Gerasimos Filippatos
MD, PhD
Arthur A. Levin
Arthur A. Levin
PhD
Douglas L. Mann
Prof. Douglas L. Mann
MD
Scott Solomon
Prof. Scott Solomon
MD
Barry Ticho
MD, PhD
Faiez Zannad
Prof. Faiez Zannad
MD, PhD

Investors

Cardior is supported by a range of prestigious life science investors.

Partners

We have established successful relationships with renowned academic partners and are always looking for new collaboration opportunities to further advance our innovative therapy approach.

Claudia Ulbrich

MD
Claudia Ulbrich
CEO & Co-Founder

Claudia Ulbrich

MD

Dr. Claudia Ulbrich, Co-Founder and CEO at Cardior, is an MD and health economist (ebs) by training with more than 25 years of management expertise in private and public biotech companies. Claudia is an integrative, experienced leader guiding international, cross-functional teams based on a broad range of experience in M&A, transaction management and consulting. She brings a strong network in venture capital, academia, and industry. Claudia combines a high level of commercial competence with a sound knowledge of medical affairs and drug development all along the valuation chain. With her excellent abilities in financing, transactions of up to 2bn EUR and strategy she is responsible for general management including P&L, corporate development, and investor relations. In 1998, Claudia founded her first biotech company, LipoNova AG (IPO in 2006), after which she served as Co-Founder, executive advisor, and interim manager of several international biotech companies, such as uniQure N.V., InoCard GmbH and t-cell Europe GmbH. Having worked as Senior Advisor at PricewaterhouseCoopers she started her own consulting business in 2008. Claudia holds several Board positions in relevant public and trade organizations.

Prof. Thomas Thum

MD, PhD
Thomas Thum
CSO & Founder

Prof. Thomas Thum

MD, PhD

Prof. Dr. Dr. med. Thomas Thum, Founder and CSO of Cardior, is a key opinion leader in cardiac diseases and the development of RNA-based therapeutics and has received numerous awards for his work. Thomas is a member of the editorial boards of the world’s most prestigious journals for cardiovascular research and an executive member of national and international research committees in the cardiovascular field. Since 2009, Thomas is Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hanover Medical School (MHH) and visiting professor at the National Heart and Lung Institute at Imperial College London since 2013. Most recently he was appointed as Director of the neighboring Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hanover, Germany. He has authored over 400 scientific publications in renowned and field-leading journals and has filed over 40 patents, nine of which have been successfully licensed to pharma companies and are currently in Phase 1/2 clinical development.

Rahul Agrawal

MD
Rahul Agrawal
CMO

Rahul Agrawal

MD

Dr. Rahul Agrawal is a board-certified cardiologist and emergency medicine physician with more than 20 years of industry experience, including global and senior medical positions focused on cardiac indications at Bayer and AstraZeneca. Rahul has led several clinical development programs in the cardiovascular, respiratory, metabolic, renal, and rare diseases space through to product approval with the FDA, EMA, PMDA, and CFDA. During his tenure, he developed global strategies to achieve the business and development goals for several cardiovascular therapeutics, in addition to leading the successful closeout of several of AstraZeneca’s global Phase 3 trials. Most recently he held the position of VP and Global Medicines Leader, Cardiovascular at AstraZeneca. Prior to AstraZeneca, Rahul was Global Director, Medical Affairs and Clinical, Global Launch Team, Pulmonary Hypertension at Bayer HealthCare. In this role, he led the marketing and branding efforts for the company’s pulmonary hypertension portfolio. Rahul holds a Doctor of Medicine from the Charité University Hospital, Berlin where he worked as a physician and scientist at the Department of Cardiology and Pulmonology. He holds an MBA from Buckinghamshire New University, United Kingdom.

Claus Andersson

PhD
Claus Andersson

Claus Andersson

PhD

Claus Andersson is a General Partner at Sunstone Life Science Ventures, where he has been part of the team since its inception, focusing on oncology, cardiology, and nucleotide modalities. So far, Claus has been active with more than 19 companies in which he has held either chairing positions or board memberships to share his experience from the last 18 years of working with entrepreneurs, co-investors, and consultants in the life sciences. Claus has extensive experience in strategy execution and technology development from various parts of the life science ecosystem – both as an entrepreneur, venture capitalist, scientist, and corporate manager. Claus holds a master’s degree in Civil Chemical Engineering from the Technical University of Denmark (DTU) and a PhD in Mathematical Statistics from the University of Copenhagen and the Humboldt University in Berlin.

Simone Botti

PhD
Simone Botti

Simone Botti

PhD

Simone Botti is a Junior Partner in the Healthcare team at INKEF. Simone brings with him more than 15 years of experience across venture capital and start-up creation and leadership. Before joining INKEF Simone was CEO of Metabomed, an early-stage cancer metabolism company he co-founded while he was Head of the Israel Bioincubator Fund at M Ventures, which he joined in 2011. Simone developed his company-building experience while at M Ventures, where he established a number of early-stage companies. During that time Simone also served as a Board Member of IATI, the Israel Advanced Technology Industries association. Previously, he was Vice President, Business Development at RAD Biomed Accelerator, one of Israel’s leading life science incubators. Simone did his PhD in Structural Biology and Neurobiology at the Weizmann Institute of Science, where he received the “Dov Elad” prize in Structural Biology.

Christoph Broja

CFA

Christoph Broja

CFA

Christoph Broja, CFA, is Managing Director at EQT Life Sciences and his focus is primarily on private companies. Prior to joining EQT Life Sciences, he was a Principal in the investment team at Boston-based Gurnet Point Capital, where he was involved in a number of investments in biopharma, medical devices, and molecular diagnostics. Prior to joining Gurnet Point Capital, Christoph worked at B-Flexion Capital in London, where he led the global financial planning process and helped set up Gurnet Point Capital in Boston. Christoph started his career as investment analyst at private equity firm Franz Haniel & Cie. in Germany. He holds a degree in Business Administration and is a CFA Charterholder.

Martin Crook

PhD
Martin Crook

Martin Crook

PhD

Martin Crook, PhD, serves as Executive Director, Business Development, Head of Oncology Search & Evaluation at Bristol Myers Squibb where he leads global scouting and diligence activities for therapeutic opportunities in oncology. Prior to joining BMS, Martin led drug discovery teams at Merck Research Laboratories to discover and develop novel pharmaceuticals for the treatment of cardiovascular disease. In 2012, Martin joined Daiichi Sankyo to source business development opportunities in cardiometabolic disease. Martin received his B.Sc. Hons. from Lancaster University in 1995, a M.Sc. in Immunology and Oncology from University of Birmingham in 1996 and his PhD, in cardiovascular disease, from the University of Bristol in 2000. Martin then went on to receive his postdoctoral training in Dr. Elizabeth Nabel’s Vascular Biology Branch of the National Heart Lung and Blood Institute (NIH) in Bethesda, Maryland.

Luc Debruyne

Luc Debruyne

Luc Debruyne is a business leader leveraging in-depth knowledge and experience of the global life sciences industry through a portfolio of non-executive and expert advisory roles. His broad functional leadership experience includes research and development, commercial, manufacturing and quality operations. Formerly Luc was a Corporate Executive Team member of GSK, where he rose to CEO of Global Vaccines from 2013 – 2018. He expanded the company’s US presence and established GSK as the #1 vaccines company worldwide. Among other advisory activities, Luc is strategy advisor to CEPI, a member of the IABoard of VIB, Life Science Board member of Greenlight Biosciences, Board member of Fund+, non-executive director at University Hospitals UZ Leuven and research fellow of Economics & Business Faculty at KU Leuven. Luc graduated from KU, Belgium, with a Master of Physical Education and Kinesiology and attended a sustainability leadership program at the University of Cambridge.

Ulrich Granzer

PhD
Ulrich Granzer

Ulrich Granzer

PhD

Ulrich Granzer, PhD, is the founder and owner of Granzer Regulatory Consulting & Services and has more than 25 years of experience in drug development and regulatory affairs. He has held senior management positions at Glaxo as Director of Regulatory Affairs and was a member of Glaxo Wellcome’s Global Regulatory Board. At BASF Pharma, Ulrich served as Vice President of Global Regulatory Centers, assuming global responsibility for Regulatory Affairs, Drug Safety, and GXP in drug development. He was responsible for the development of small molecules as well as several biological compounds in the indications of obesity, stroke, septic shock, and rheumatoid arthritis at Knoll. He was instrumental to the program for the first fully human anti-TNF antibody, now marketed as Humira. Before starting his own consultancy in 2002, Ulrich joined Bayer as Vice President of Global Regulatory Affairs, whose responsibility extended over all regulatory aspects of development and submission projects. He received his graduate degree from Philipps University of Marburg and a doctorate degree from Eberhard Karls Universität Tübingen.

Russell Greig

PhD
Russell Greig
Chairman

Russell Greig

PhD

Dr. Russell G. Greig graduated from the University of Manchester, UK with a BSc and PhD in Biochemistry and built a substantial career at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Prior to joining SR One, he served as President of GlaxoSmithKline’s Pharmaceuticals International from 2003 to 2008 and Senior Vice President of worldwide development from 2000-2003, as well as on the GlaxoSmithKline corporate executive team. Over the last decade, Dr. Greig has served as Chairman and board member for a range of innovative biopharmaceutical companies in the US and in Europe including overseeing a number of successful exits.

Markus Hosang

PhD
Markus Hosang
Vice-chairman

Markus Hosang

PhD

Markus Hosang, PhD, is a General Partner and Managing Director at BioMedPartners in Basel. He serves on the boards of Unitectra AG, Aleva Neurotherapeutics, Anergis, Hookipa Biotech, and Imevax. Earlier in his career, Markus was a venture partner at MPM Capital, where he managed their European office in Munich and served on the boards of several of their European portfolio companies including Omrix Pharmaceuticals, Kourion, IDEA and Atugen. Before that, Markus was at Roche in Basel for nearly 20 years, where he held several senior management positions. He obtained his PhD in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington Medical School in Seattle where he published numerous articles in peer-reviewed journals.

Prof. Johann Bauersachs

MD

Prof. Johann Bauersachs

MD

Johann Bauersachs, MD, is Full Professor and Head of the Department of Cardiology and Angiology at Hannover Medical School. As an interventional cardiologist, his research focuses on acute coronary syndromes, left ventricular healing and remodeling, and acute and chronic heart failure. He is an expert on non-coding RNAs in the pathophysiology and treatment of peripartum cardiomyopathy as well as aldosterone and mineralocorticoid receptor-mediated mechanisms. Johann is a Board member of the German Cardiac Society. He is Study Chair of the DIGIT-HF study investigating the effect of digitoxin in patients with advanced heart failure and is actively involved in many other clinical trials. He received his medical degree from the University of Freiburg, Germany, and was trained as Clinical and Research Fellow at the Universities of Frankfurt, Heidelberg/Mannheim and Wuerzburg.

Prof. Javed Butler

MD
Javed Butler

Prof. Javed Butler

MD

Prof. Javed Butler is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center. Prior to joining the University of Mississippi, he was Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University. Javed serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America as well as editorial boards of peer-reviewed cardiovascular journals. He received his medical degree from the Aga Khan University and completed residency training at Yale University. Javed holds a Master of Public Health degree from Harvard University and MBA from Emory University. He has authored more than 800 peer-reviewed publications and was rewarded with the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.

Prof. Perry Elliott

MD

Prof. Perry Elliott

MD

Perry Elliott is a Professor of Cardiovascular Medicine at UCL and a Senior Investigator of the UK National Institute for Health Research (NIHR). He is Director of the UCL Centre for Heart Muscle Disease and a Consultant Cardiologist in the Centre for Inherited Cardiovascular Disease at St. Bartholomew’s Hospital London, UK. He was appointed as Director of the UCL Institute of Cardiovascular Science in 2021 and is President of Cardiomyopathy UK, Europe’s foremost charity for patients with heart muscle disease. Perry has presided as chairman over many heart-related committees including the ESC Working Group on Myocardial and Pericardial Diseases, the Executive Committee for the European Outcomes Research Programme registry on cardiomyopathies, and the 2014 ESC Guideline Task Force on Hypertrophic Cardiomyopathy. He is currently the Chairman of the European Society of Cardiology (ESC) Heart Academy and the ESC Council on Cardiovascular Genomics. Perry has authored more than 700 peer-reviewed papers on heart disease and served as a Deputy Editor of the Heart Journal, International Journal of Cardiology and is currently the Executive Editor for the European Heart Journal.

Gerasimos Filippatos

MD, PhD

Gerasimos Filippatos

MD, PhD

Dr. Filippatos is Professor and Chairman of the Department of Cardiology and Director of the Heart Failure and Cardioncology Unit at the Attikon University Hospital, Athens, Greece. He was Dean of the School of Medicine, University of Cyprus. He studied Medicine at the University of Patras and earned his doctorate Cum Laude from the University of Athens. He completed his clinical training in Chicago, USA, and Cambridge, UK. He is past President of the Heart Failure Association of the ESC. He has served in the ESC Practice Guidelines Committee and the ACC/AHA Heart Failure Guidelines Writing Committee and as International Governor of the ACCP. He was Associate Editor of the European Heart Journal and he is Senior Consulting Editor of JACC-HF. He has published over 500 articles in peer-reviewed journals and authored more than 30 book chapters including the “Acute Heart Failure” chapter in Braunwald. He has (co)-edited 5 books including the ESC Textbook of Acute and Intensive Cardiac Care, Highly Commended in the British Medical Association Medical Book Awards, and the books “Heart Failure: The Expert’s Approach” and “Treatment Algorithms in Heart Failure”. Prof. Filippatos is in the Thomson Reuters/Clarivate list of Highly Cited Researchers since 2015. He is Honorary Member of many Cardiac Societies.

Arthur A. Levin

PhD
Arthur A. Levin

Arthur A. Levin

PhD

Arthur A. Levin, PhD, is Avidity Bioscience’s Executive Vice President of Research and Development with nearly 30 years of experience in the pharmaceutical industry. He has been involved in the development of more than 20 oligonucleotide therapeutics, including both approved antisense drugs. Prior to joining Avidity, Arthur ran research and development at miRagen Therapeutics and was Chief Development Officer at Santaris Pharma where he led the efforts on the first microRNA-targeting therapeutic currently in Phase 2 clinical trials. Before joining Santaris Pharma, he consulted for leading biotechnology and pharmaceutical companies, conducting research and development in RNA-based therapies. Prior to consulting, Arthur was Senior Vice President of Development at Isis Pharmaceuticals. He holds a PhD in Toxicology from the University of Rochester School of Medicine and Dentistry, New York and a B.Sc. in Biology from Muhlenberg College. He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. In addition, he authored more than 70 papers and book chapters.

Prof. Douglas L. Mann

MD
Douglas L. Mann

Prof. Douglas L. Mann

MD

Prof. Dr. Douglas L. Mann is the Lewin Distinguished Professor of Cardiovascular Disease and Professor of Cell Biology and Physiology at the Washington University School of Medicine in St. Louis. Douglas’ primary research interest has been the molecular and cellular basis of heart failure. He is Editor-in-Chief of JACC: Basic to Translational Science and is on the Editorial Board for a number of other leading cardiovascular journals. Additionally, he is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, the American Association for the Advancement of Science, and the Association of University Cardiologists, as well as a member and past-president of the Heart Failure Society of America. Douglas received his medical degree from Temple University School of Medicine in Philadelphia and completed fellowships in clinical cardiology at the University of California San Diego, and Massachusetts General Hospital in Boston. He is the author of numerous peer-reviewed articles on the role of inflammatory mediators in cardiac remodeling and myocardial recovery.

Prof. Scott Solomon

MD
Scott Solomon

Prof. Scott Solomon

MD

Prof. Scott D. Solomon, MD, is The Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School, and Senior Physician at Brigham and Women’s Hospital. He directs the Clinical Trials Outcomes Center and the Cardiac Imaging Core Laboratory at Brigham and Women’s Hospital. Scott has pioneered the use of cardiac imaging in cardiovascular drug and device development and use of imaging in clinical trials and has played a leading role in many international clinical trials in heart failure, hypertension, and myocardial infarction. He led the first positive Phase II trial in HFpEF, and his work led to the first FDA indication for a therapy for heart failure with ejection fraction > 40%. Scott received his A.B. from Williams College and his MD from Harvard Medical School and has authored more than 800 peer-reviewed articles, reviews, and editorials, two textbooks of cardiac imaging. He serves as editor for Braunwald’s Heart Disease, the premiere textbook of cardiovascular medicine.

Barry Ticho

MD, PhD

Barry Ticho

MD, PhD

Barry Ticho, MD, PhD, is currently Chief Medical Officer at Stoke Therapeutics where he is responsible for the company’s efforts to develop first-in-class RNA based medicines that treat severe genetic diseases. As Co-Founder and Board Member of Verve Therapeutics, Barry combines entrepreneurial and corporate expertise with a sound understanding of cardiovascular diseases. With years of experience in R&D from Moderna, Pfizer and Biogen, he brings an in-depth knowledge of developing mRNA treatments for cardiovascular and metabolic diseases. Barry obtained his MD and PhD degrees from the University of Chicago and has served as a member of the clinical staff at Harvard Medical School and Massachusetts General Hospital, where he conducted laboratory research on the regulation of cardiac development.

Prof. Faiez Zannad

MD, PhD
Faiez Zannad

Prof. Faiez Zannad

MD, PhD

Prof. Faiez Zannad, MD, Cardiologist and heart failure specialist, PhD in Clinical Pharmacology, FESC is Emeritus Professor of Therapeutics at the University of Lorraine and former Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux”, Nancy, France. Faiez has led two EU FP7 grant programs and is part of oversight committees in major clinical trials and made significant contributions to evidence-based heart failure therapy, as well as in major comorbid diseases. He served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association. Faiez is organizing the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international think-tank gathering dedicated to the science of clinical trials, with meetings in Paris, Washington DC, Middle East and Asia. As of June 2021, Faiez has published more than 940 peer-reviewed papers. In 2014, he was awarded the European Society of Hypertension Paul Milliez Award and in 2017 the Lifetime Achievement Award from the ESC Heart Failure Association.